NASDAQ:AXNX - Axonics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $77.86
  • Forecasted Upside: 7.57 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$72.38
▲ +2.3 (3.28%)

This chart shows the closing price for AXNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Axonics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXNX

Analyst Price Target is $77.86
▲ +7.57% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Axonics in the last 3 months. The average price target is $77.86, with a high forecast of $87.00 and a low forecast of $65.00. The average price target represents a 7.57% upside from the last price of $72.38.

This chart shows the closing price for AXNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Axonics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/2/2022Morgan StanleyBoost Price TargetOverweight$73.00 ➝ $80.00Low
8/2/2022Needham & Company LLCBoost Price TargetBuy$60.00 ➝ $77.00Low
8/2/2022Truist FinancialBoost Price TargetBuy$75.00 ➝ $85.00Low
8/2/2022Wells Fargo & CompanyBoost Price TargetOverweight$80.00 ➝ $87.00Low
8/2/2022Piper SandlerBoost Price TargetOverweight$77.00 ➝ $82.00Low
7/20/2022Truist FinancialBoost Price TargetBuy$64.00 ➝ $75.00Low
5/6/2022Piper SandlerBoost Price Target$75.00 ➝ $77.00High
4/5/2022Wolfe ResearchInitiated CoverageOutperform$69.00Medium
3/8/2022Needham & Company LLCReiterated RatingBuy$62.00Medium
3/2/2022Bank of AmericaInitiated CoverageBuy ➝ BuyMedium
2/25/2022SVB LeerinkBoost Price TargetOutperform$60.00 ➝ $65.00High
2/25/2022Morgan StanleyLower Price TargetOverweight$73.00 ➝ $69.00High
1/7/2022Morgan StanleyLower Price TargetOverweight$74.00 ➝ $73.00High
12/14/2021Needham & Company LLCLower Price TargetBuy$71.00 ➝ $62.00High
11/5/2021Needham & Company LLCLower Price TargetBuy$78.00 ➝ $71.00High
11/5/2021SVB LeerinkBoost Price TargetOutperform$80.00 ➝ $85.00High
11/5/2021Piper SandlerLower Price TargetOverweight$78.00 ➝ $75.00High
9/21/2021Needham & Company LLCReiterated RatingBuy$78.00High
8/9/2021Morgan StanleyBoost Price TargetOverweight$62.00 ➝ $74.00Low
8/6/2021BarclaysBoost Price TargetOverweight$74.00 ➝ $79.00High
8/6/2021Piper SandlerBoost Price TargetOverweight$75.00 ➝ $78.00High
7/20/2021SVB LeerinkReiterated RatingOutperformHigh
7/12/2021BarclaysInitiated CoverageOverweight$74.00High
6/28/2021Needham & Company LLCBoost Price TargetBuy$72.00 ➝ $78.00High
5/7/2021Needham & Company LLCBoost Price TargetBuy$71.00 ➝ $72.00High
5/7/2021Morgan StanleyBoost Price TargetOverweight$58.00 ➝ $62.00High
5/7/2021Piper SandlerReiterated RatingOverweight$70.00 ➝ $75.00High
5/3/2021Piper SandlerBoost Price TargetOverweight$70.00 ➝ $75.00Low
3/24/2021Needham & Company LLCBoost Price TargetPositive ➝ Buy$66.00 ➝ $71.00High
3/12/2021Piper SandlerBoost Price TargetPositive ➝ Overweight$64.00 ➝ $68.00Low
2/26/2021Needham & Company LLCBoost Price TargetBuy$62.00 ➝ $66.00High
1/26/2021Robert W. BairdBoost Price TargetOutperform$58.00 ➝ $65.00High
1/26/2021Piper SandlerBoost Price TargetOverweight$57.00 ➝ $64.00High
1/7/2021Morgan StanleyBoost Price TargetOverweight$53.00 ➝ $58.00N/A
11/5/2020Truist FinancialBoost Price Target$50.00 ➝ $58.00High
11/5/2020Wells Fargo & CompanyBoost Price Target$51.00 ➝ $57.00High
11/5/2020Robert W. BairdBoost Price TargetBuy ➝ Outperform$52.00 ➝ $58.00High
11/5/2020Piper SandlerBoost Price TargetOverweight$50.00 ➝ $57.00High
11/5/2020Needham & Company LLCBoost Price TargetBuy$57.00 ➝ $62.00High
10/23/2020GuggenheimInitiated CoverageBuy$77.00High
10/12/2020SVB LeerinkBoost Price TargetOutperform$59.00 ➝ $60.00Medium
9/2/2020Robert W. BairdInitiated CoverageOutperform$52.00High
8/10/2020Morgan StanleyBoost Price TargetOverweight$42.00 ➝ $53.00Low
8/7/2020SVB LeerinkBoost Price TargetOutperform$48.00 ➝ $59.00Medium
8/3/2020Needham & Company LLCReiterated RatingBuy$48.00 ➝ $57.00Low
7/27/2020Piper SandlerReiterated RatingBuy$45.00High
7/22/2020SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $48.00Low
7/13/2020Needham & Company LLCReiterated RatingBuy$48.00High
6/5/2020Wells Fargo & CompanyBoost Price TargetOverweight$40.00 ➝ $42.00High
5/6/2020Morgan StanleyBoost Price TargetOverweight$36.00 ➝ $42.00High
4/21/2020Piper SandlerLower Price TargetOverweight$48.00 ➝ $44.00High
4/8/2020Wells Fargo & CompanyLower Price TargetOverweight$47.00 ➝ $35.00Medium
3/27/2020Morgan StanleyLower Price TargetBuy$42.00 ➝ $36.00Low
3/9/2020Needham & Company LLCReiterated RatingBuy$48.00High
3/5/2020SunTrust BanksBoost Price TargetIn-Line ➝ Buy$38.00 ➝ $48.00High
3/5/2020Piper SandlerReiterated RatingOverweight$44.00 ➝ $48.00High
1/7/2020SunTrust BanksInitiated CoverageBuy$38.00Low
12/6/2019Wells Fargo & CompanyReiterated RatingBuyLow
11/5/2019Needham & Company LLCReiterated RatingBuy$48.00Low
11/1/2019Piper Jaffray CompaniesInitiated CoverageOverweight$39.00 ➝ $39.00High
10/23/2019Needham & Company LLCReiterated RatingBuyLow
10/21/2019BarclaysInitiated CoverageOverweight$43.00Low
9/17/2019SVB LeerinkInitiated CoverageOutperform$45.00High
9/10/2019Bank of AmericaBoost Price TargetBuy$35.00 ➝ $40.00High
9/3/2019Needham & Company LLCInitiated CoverageBuy$43.00 ➝ $43.00Low
7/2/2019Wells Fargo & CompanyBoost Price TargetOutperform$35.00 ➝ $47.00Low
6/13/2019Bank of AmericaBoost Price TargetBuy$30.00 ➝ $35.00High
5/10/2019SunTrust BanksBoost Price TargetBuy$33.00High
3/5/2019SunTrust BanksBoost Price TargetPositive ➝ Buy$26.00High
12/2/2018Morgan StanleyInitiated CoverageOverweight$21.00 ➝ $14.92High
11/26/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$20.00Medium
11/26/2018Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$22.00Medium
11/26/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$21.00Medium
11/26/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$23.00Medium
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
1/14/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/13/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
3/15/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/14/2022
  • 4 very positive mentions
  • 17 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
5/14/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/13/2022
  • 6 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/12/2022

Current Sentiment

  • 6 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Axonics logo
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Read More

Today's Range

Now: $72.38
Low: $69.29
High: $72.48

50 Day Range

MA: $60.73
Low: $48.26
High: $72.38

52 Week Range

Now: $72.38
Low: $38.41
High: $79.81

Volume

445,010 shs

Average Volume

543,673 shs

Market Capitalization

$3.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Axonics?

The following Wall Street sell-side analysts have issued research reports on Axonics in the last year: Bank of America Co., Morgan Stanley, Needham & Company LLC, Piper Sandler, SVB Leerink LLC, Truist Financial Co., Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for AXNX.

What is the current price target for Axonics?

7 Wall Street analysts have set twelve-month price targets for Axonics in the last year. Their average twelve-month price target is $77.86, suggesting a possible upside of 7.6%. Wells Fargo & Company has the highest price target set, predicting AXNX will reach $87.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $65.00 for Axonics in the next year.
View the latest price targets for AXNX.

What is the current consensus analyst rating for Axonics?

Axonics currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AXNX will outperform the market and that investors should add to their positions of Axonics.
View the latest ratings for AXNX.

What other companies compete with Axonics?

How do I contact Axonics' investor relations team?

Axonics' physical mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company's listed phone number is (866) 722-5738 and its investor relations email address is [email protected] The official website for Axonics is www.axonics.com. Learn More about contacing Axonics investor relations.